This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Sanofi's (SNY) Aubagio Gets EU Nod for MS in Pediatric Patients
by Zacks Equity Research
The European Commission approves Sanofi's (SNY) Aubagio for the treatment of pediatric patients aged 10 to 17 years with relapsing-remitting multiple sclerosis.
Biogen (BIIB) Ends Development of Anti-Tau Alzheimer's Drug
by Zacks Equity Research
Biogen (BIIB) ends development of investigational anti-tau antibody, gosuranemab for treating Alzheimer's disease after the phase II TANGO study showed no benefit to patients.
Incyte (INCY) Faces Delay in Approval of Atopic Dermatitis Cream
by Zacks Equity Research
Incyte's (INCY) NDA review for ruxolitinib cream for the treatment of atopic dermatitis gets extended.
Pharma Stock Roundup: FDA Approval for NVO, PFE Products & Other Updates
by Kinjel Shah
FDA approves Novo Nordisk's (NVO) obesity treatment, Wegovy and Pfizer's (PFE) 20-valent pneumococcal conjugate vaccine, Prevnar 20.
Incyte's (INCY) sNDA Review for Jakafi in GVHD Gets Extended
by Zacks Equity Research
Incyte's (INCY) sNDA review of Jakafi for the indication of steroid-refractory chronic GVHD gets extended by three months.
Biogen (BIIB) Up as FDA Approves Alzheimer'S Drug Aducanumab
by Zacks Equity Research
FDA approves Biogen's (BIIB) Aduhelm (aducanumab), making it the first medicine to be approved to reduce the clinical decline associated with Alzheimer's disease.
3 Drug Stocks Rise as FDA Okays Biogen Alzheimer's Drug
by Kinjel Shah
FDA approves Biogen's (BIIB) Alzheimer's disease ("AD") drug, Aduhelm (aducanumab). Stocks of Eli Lilly (LLY), Cassava Sciences (SAVA) and Annovis Bio (ANVS) rise as they also have AD candidates in their portfolio.
Novartis (NVS) Posts Positive Data on Kidney Disease Candidate
by Zacks Equity Research
Novartis' (NVS) rare kidney disease candidate meets its primary goal in a phase II study.
Novartis (NVS) Announces Data on Radioligand Therapy at ASCO
by Zacks Equity Research
Novartis (NVS) posts results from a late-stage study on radioligand therapy at the 2021 ASCO.
AbbVie's (ABBV) Skyrizi Succeeds in Crohn's Maintenance Study
by Zacks Equity Research
AbbVie (ABBV) is focusing on label expansion of Skyrizi beyond plaque psoriasis. The drug achieves endoscopic response and clinical remission as maintenance treatment for Crohn's disease study.
Amgen's (AMGN) KRAS Inhibitor Gets FDA Nod for Lung Cancer
by Zacks Equity Research
FDA approval of Amgen's (AMGN) Lumakras for KRAS G12C-mutated locally advanced or metastatic non-small cell lung cancer is based on positive data from the phase II CodeBreaK 100 study.
Pharma Stock Roundup: JNJ Cancer Drug Gets FDA Nod, PFE, GSK, SNY Begin New Studies
by Kinjel Shah
Sanofi (SNY) and Glaxo's (GSK) COVID-19 vaccine candidate enters phase III. FDA approves J&J's (JNJ) Rybrevant (amivantamab) for a rare lung cancer
Novartis (NVS) & Molecular Partners Initiate Study for COVID-19
by Zacks Equity Research
Novartis (NVS) initiates study for investigating its novel DARPin therapeutic candidate, ensovibep (MP0420), for the treatment of COVID-19, in collaboration with Molecular Partners.
PTC Therapeutics' (PTCT) PTC923 Gets Orphan Drug Tag in US & EU
by Zacks Equity Research
The FDA and the European Commission bestow Orphan Drug status to PTC Therapeutics' (PTCT) PTC923 for the treatment of hyperphenylalaninemia.
J&J's (JNJ) Multiple Sclerosis Drug Ponvory Gets EU Approval
by Zacks Equity Research
J&J's (JNJ) oral multiple sclerosis drug, Ponvory, receives approval in Europe after demonstrating superior efficacy in reducing annual relapses compared to Sanofi's Aubagio in clinical studies.
Pharma Stock Roundup: GSK/SNY COVID-19 Vaccine Data, PFE's New EU Supply Deal
by Kinjel Shah
Sanofi (SNY) and Glaxo's (GSK) COVID-19 vaccine shows strong antibody response in phase II. Lilly's fifth phase III study on tirzepatide meets all key endpoints
Incyte (INCY) Announces Positive Results From Vitiligo Study
by Zacks Equity Research
Incyte (INCY) announces positive data from phase III studies on ruxolitinib cream for the treatment of vitiligo.
Ionis (IONS) Q1 Loss Widens Year Over Year, Sales Miss
by Zacks Equity Research
Ionis (IONS) Q1 adjusted loss per share was wider than the year-ago figure. The company maintains its guidance for 2021.
Incyte (INCY) Q1 Earnings Beat, Sales Miss on Soft Jakafi
by Zacks Equity Research
Incyte (INCY) beats earnings estimates in the first quarter but misses sales figure as Jakafi sales were weaker than expected.
3 Big Drugmaker Stocks to Watch Out For Amid Pandemic Woes
by Kinjel Shah
Most Large Cap Pharmaceuticals industry players' Q1 results have been disappointing. Launch of COVID-19 vaccines and medicines is playing a crucial role in driving the industry. PFE, JNJ and AZN may prove to be good additions to your portfolio.
The Zacks Analyst Blog Highlights: Eli Lilly, Merck, GlaxoSmithKline, Novartis and Johnson & Johnson
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Eli Lilly, Merck, GlaxoSmithKline, Novartis and Johnson & Johnson
Pharma Stock Roundup: Big Drugmakers' Q1 Earnings, Resumption of JNJ US COVID-19 Jabs
by Kinjel Shah
Several large drugmakers announce Q1 earnings. Many miss estimates for both earnings and sales. J&J (JNJ) resumes COVID-19 vaccination in the United States.
Alnylam's (ALNY) Q1 Loss Narrower Than Expected, Revenues Beat
by Zacks Equity Research
Alnylam (ALNY) beat estimates for both earnings and revenues in the first quarter of 2021.
Pharma/Biotech Stocks' Q1 Earnings Queued for Apr 29: MRK, BMY & More
by Zacks Equity Research
Let us take a look at what is in store for some of the pharma/biotech stocks, which are scheduled to report on Apr 29.
Novartis (NVS) Q1 Earnings & Sales Miss Estimates on COVID-19 Woes
by Zacks Equity Research
Novartis (NVS) reports lower-than-expected first-quarter results, as the pandemic continues to negatively impact sales.